Healthcare, Pharma & Life Sciences

Antengene Data Show CD73 Inhibitor Boosts Selinexor Efficacy in Myeloma

Image
Antengene Data Show CD73 Inhibitor Boosts Selinexor Efficacy in Myeloma

Shanghai and Hong Kong – September 17, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) has published preclinical data showing that combining its CD73 inhibitor ATG-037 with selinexor suppressed tumor growth by 62% in a multiple myeloma mouse model, versus 31% for ATG-037 alone and 43% for selinexor alone. The peer-reviewed paper, developed with the Department of Hematology at Peking University Third Hospital, appears in Cancer Gene Therapy, an SCI journal under Springer Nature (DOI: 10.1038/s41417-026-01078-9).

Accro's AC-101 Enters NMPA Rare Disease Pilot for Blau Syndrome

Suzhou – – September 17, 2026 -- Accro Bioscience said AC-101 tablets have been included in the National Medical Products Administration's Center for Drug Evaluation (CDE) "Caring Plan-Extension" pilot program, targeting Blau syndrome as the proposed indication, with the public notice period closing September 17, 2026.

NMPA pilot program aims to accelerate rare disease drug development in China

The Caring Plan-Extension pilot, run by China's CDE, is designed to encourage innovative drug development for rare diseases. Accro Bioscience confirmed the inclusion took effect September 17, 2026, China Standard Time (UTC+8).

FDA granted AC-101 Rare Pediatric Disease designation three months earlier

The U.S. Food and Drug Administration awarded AC-101 Rare Pediatric Disease (RPD) designation for Blau syndrome in June 2026, ahead of the Chinese regulatory step.

Whitehawk Data Show PTK7 Target Stable After Lung Cancer Treatment

Image
Whitehawk Data Show PTK7 Target Stable After Lung Cancer Treatment

Morristown, N.J. – September 17, 2026 -- Whitehawk Therapeutics (Nasdaq: WHWK) presented real-world data at the IASLC 2026 World Conference on Lung Cancer in Seoul showing that PTK7 expression remains stable in pretreated, EGFR wild-type non-small cell lung cancer (NSCLC), reinforcing the target biology behind its Phase 1 antibody-drug conjugate (ADC) HWK-007.

RYBREVANT Combo Extends Survival to 34.3 Months in Lung Cancer Trial

Image
RYBREVANT Combo Extends Survival to 34.3 Months in Lung Cancer Trial

Seoul – September 17, 2026 -- Johnson & Johnson reported that its RYBREVANT (amivantamab-vmjw) plus chemotherapy combination extended median overall survival to 34.3 months in patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer, compared with 27.9 months for chemotherapy alone, according to final data from the Phase 3 PAPILLON study.

Combination therapy nearly doubles historical survival benchmarks

The result marks the longest reported median overall survival for this patient population, which has historically faced a five-year survival rate of just 8 percent and a median overall survival ranging from 16 to 24 months. EGFR exon 20 insertion mutations account for approximately 12 percent of all EGFR mutations and have proven difficult to treat with existing targeted therapies.

IonOpticks Launches Aurora Series 5 With CoreJet Emitter Tech

Image
IonOpticks Launches Aurora Series 5 With CoreJet Emitter Tech

Melbourne – September 17, 2026 -- IonOpticks has released Aurora Series 5, a nano-LC column platform that sustained over 10,000 unique protein identifications across more than 1,000 injections in extended laboratory testing, without a rise in backpressure beyond 1,400 runs.

Extended testing confirms durability across 1,400-plus injections on an 8-minute, 120-samples-per-day method

Testing was conducted on a Thermo Scientific Vanquish Neo UHPLC coupled to an Orbitrap Astral Zoom mass spectrometer. IonOpticks says the results allow laboratories to run nanoflow-level depth and sensitivity as a routine, high-throughput workflow rather than reserving it for select experiments.

Ris-Rez Cuts Death Risk 54% in Phase III Relapsed Lung Cancer Trial

Image
Ris-Rez Cuts Death Risk 54% in Phase III Relapsed Lung Cancer Trial

Seoul – September 17, 2026 -- Risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, reduced the risk of death by 54% compared with topotecan in patients with relapsed small-cell lung cancer, according to Phase III ARTEMIS-008 trial results presented at the IASLC 2026 World Conference on Lung Cancer.

Ris-Rez extends median overall survival to 18.5 months versus 10.3 months for topotecan

The multicenter, open-label trial (NCT06498479) randomized 461 patients in China 1:1 to receive Ris-Rez at 8.0 mg/kg every three weeks or topotecan at 1.2 mg/m2 on days 1 through 5 every three weeks. More than 80% of enrolled patients had previously received PD-(L)1 inhibitors. At the September 17, 2026 data cutoff, after a median follow-up of 12.2 months, the hazard ratio for death favored Ris-Rez at 0.46 (95% CI, 0.35–0.62; P0.0001), with the survival benefit consistent across relevant subgroups.

Akeso's Ivonescimab Cuts Death Risk 27% vs Keytruda in NSCLC Trial

Hong Kong – September 17, 2026 -- Akeso, Inc. (9926.HK) reported that its bispecific antibody ivonescimab reduced the risk of death by 27% compared with Merck's pembrolizumab in a Phase III trial of PD-L1-positive non-small cell lung cancer (NSCLC), with results presented as a Late-Breaking Abstract at the 2026 World Conference on Lung Cancer (WCLC).

Ivonescimab extends median survival to 30.8 months in head-to-head trial

In the intention-to-treat population of the HARMONi-2 study (AK112-303), patients treated with ivonescimab monotherapy achieved a median overall survival (OS) of 30.8 months versus 22.6 months for pembrolizumab (HR=0.73; 95% CI: 0.57–0.95; P=0.009). The data cutoff was September 17, 2026, with a median follow-up of 36 months and 234 OS events recorded. Professor Caicun Zhou, principal investigator and IASLC President, is scheduled to deliver the full oral presentation on September 15.

IASLC Waives Membership Fees for Clinicians in Low-Income Nations

Denver – September 17, 2026 -- The International Association for the Study of Lung Cancer (IASLC) has launched a Complimentary IASLC Full Membership program for healthcare professionals in World Bank-designated low-income and lower-middle-income economies, eliminating financial barriers to its global thoracic oncology network.

Board approves fee waiver to widen access to research and clinical resources

The IASLC Board of Directors approved the initiative this spring, extending full membership benefits at no cost to clinicians, researchers, nurses, allied health professionals and patient advocates in eligible countries. Eligibility is determined annually using World Bank country income classifications.

Aignostics Launches PathoSearch, AI Visual Search for Pathology Cases

Image
Aignostics Launches PathoSearch, AI Visual Search for Pathology Cases

Berlin – September 17, 2026 -- Aignostics has opened early access to PathoSearch, a visual search engine that retrieves diagnosed reference pathology cases from a single screenshot of an H&E slide, targeting the rare and complex cases that make up as much as 20% of a pathologist's caseload.

Database already spans 310,000 slides across 300 diagnostic entities

PathoSearch currently references more than 310,000 whole slide images drawn from over 35,000 cases, covering 300-plus diagnostic entities and 27-plus organs. The system is on track to exceed one million whole slide images by general availability. Coverage follows the WHO Classification of Tumours, focusing on malignant tumours across five organ groups -- thoracic, digestive, soft tissue and bone, female genital, and urinary and male genital -- with full coverage of all WHO-classified malignancies planned.

SystImmune's Iza-bren Hits Phase 3 Dose in Global Lung Cancer Trial

Image
SystImmune's Iza-bren Hits Phase 3 Dose in Global Lung Cancer Trial

Seoul – September 17, 2026 -- SystImmune, Inc. announced that new global Phase 1 data support 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose for iza-bren (izalontamab brengitecan), a bispecific EGFRxHER3 antibody drug conjugate, in previously treated EGFR-mutated metastatic non-small cell lung cancer (NSCLC).

Randomized Phase 1 cohort confirms higher efficacy at the 2.5 mg/kg dose level

The abstract, presented in an oral session at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, evaluated iza-bren across three dose levels in a randomized dose-expansion cohort. Patients enrolled had EGFR-mutated metastatic NSCLC and had previously received a third-generation EGFR inhibitor. Results showed promising antitumor activity with a manageable safety profile, with the highest efficacy observed at the 2.5 mg/kg dose.